Accelerating Generic Drug Time-To-Market: Integrative Review of Operational Excellence, Strategic Knowledge Management and Cross-Functional Bottlenecks

Abstract

A generic drug can achieve all its technical milestones on time and still get to patients late. Time is seldom lost within a single department, but it gathers up in the intervals between them. The relevant literature is spread across pharmaceutical development, knowledge management, organizational learning, business-process management, cross-functional integration, project scheduling and operational excellence, and has not yet been synthesized. This review combines that work, giving priority to generic and broader pharmaceutical development and using studies from other settings only where their mechanisms are transferable. It draws on 65 sources, from empirical studies to regulatory guidance, identified through database searches and reference tracking. There are three interrelated processes. When a decision must be made, technical and regulatory experience must be at hand. Recurring management processes and handovers must be defined so that they are predictable. The project schedule must separate avoidable waiting and preventable rework from the necessary science and the unavoidable waiting that no management system can shorten. Whether a local delay then shifts the launch date depends on concurrency, dependencies and available float. The proposed framework links strategic knowledge management to process harmonization and handover reliability, and these in turn to lower operational loss and shorter time-to-market. Evidence on generic development from the laboratory to the market is still limited, and the proposed relationships have not yet been tested empirically. The review provides a basis for reducing preventable launch delay without weakening scientific rigor, product quality or regulatory compliance.